- Home
- KINS vs NMRA Comparison
KINS vs NMRA Comparison
Compare KINS & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | KINS | NMRA |
|---|---|---|
| Founded | 1886 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.5M | 302.0M |
| IPO Year | 2013 | 2023 |
Fundamental Metrics
Financial Performance| Metric | KINS | NMRA |
|---|---|---|
| Price | $19.18 | $0.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 73.8K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 94.59 | 5.23 |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $214,867,301.00 | N/A |
| Revenue This Year | $24.23 | N/A |
| Revenue Next Year | $18.05 | N/A |
| P/E Ratio | $29.03 | ★ N/A |
| Revenue Growth | ★ 38.50 | N/A |
| 52 Week Low | $13.79 | $0.71 |
| 52 Week High | $20.90 | $3.65 |
Technical Indicators
Market Signals| Indicator | KINS | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.40 | 16.32 |
| Support Level | $18.68 | N/A |
| Resistance Level | $19.42 | $1.74 |
| Average True Range (ATR) | 0.46 | 0.09 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 29.60 | 2.10 |
Price Performance
Historical ComparisonAbout KINS Kingstone Companies Inc.
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.